

Infusion Therapy Order

Patient Name: _____ Date of Birth: _____

Address: _____ Height: _____ Weight: _____

Phone: _____ Allergies: _____

Primary Diagnosis: _____ ICD-10 Code: _____

Requested Infusion Start Date: _____ Frequency: _____

Infusion Location: _____ Duration: _____

Insurance Authorization: _____

Prescriber Information:

Prescriber Name: _____ NPI: _____

Address: _____

Phone: _____ Fax: _____

Prescriber Signature: _____

*****Please use a single line and mark through any orders you do not want if it is pre-checked...The Appointment request is required, but make edits to the Interval and Duration as needed...Please add any additional orders on the last page*****

SJH PEGFILGRASTIM

version 3/14/2024

Appointment Request

Interval Defer Until Duration

☒ **SJH ONCBCN INJECTION APPOINTMENT REQUEST**

☒ Injection Appointment Request

Status: Future, Expected: S Approximate, Expires: S+365, Sched. Duration: 30 minutes, Sched. Tolerance: Schedule appointment at most 2 days before or at most 2 days after

Supportive Care

	Interval	Defer Until	Duration
☒ SJH ONCBCN SUPPORTIVE CARE PEGFILGRASTIM (BIOSIMILARS) INJ 6MG			
☐ pegfilgrastim-pbbk (FYLNETRA) injection 6 mg			
6 mg, subcutaneous, Once, Starting at treatment start time - Allow the prefilled syringe to reach room temperature (for a minimum of 30 minutes) before administering. - Pegfilgrastim should be administered at least 24 hours after administration of cytotoxic chemotherapy. Pegfilgrastim should not be administered within 14 days prior to the next cycle of cytotoxic chemotherapy. **Preferred Biosimilar**			
☐ pegfilgrastim-jmdb (FULPHILA) injection 6 mg			
6 mg, subcutaneous, Once, Starting at treatment start time Prior to use, remove the carton from the refrigerator and allow the prefilled syringe to reach room temperature for a minimum of 15-30 minutes. Do not administer to persons with latex allergies. Pegfilgrastim should be administered at least 24 hours after administration of cytotoxic chemotherapy. Pegfilgrastim should not be administered within 14 days prior to the next cycle of cytotoxic chemotherapy. **Secondary Biosimilar**			
☐ pegfilgrastim-fpgk (STIMUFEND) injection 6 mg			
6 mg, subcutaneous, Once, Starting at treatment start time - Allow the prefilled syringe to reach room temperature (for a minimum of 30 minutes) before administering. - Pegfilgrastim should be administered at least 24 hours after administration of cytotoxic chemotherapy. Pegfilgrastim should not be administered within 14 days prior to the next cycle of cytotoxic chemotherapy. **Alternative Biosimilar**			
☐ pegfilgrastim-cbqv Syrg 6 mg			
6 mg, subcutaneous, Once, Starting at treatment start time - Allow the prefilled syringe to reach room temperature (for a minimum of 30 minutes) before administering. - Pegfilgrastim should be administered at least 24 hours after administration of cytotoxic chemotherapy. Pegfilgrastim should not be administered within 14 days prior to the next cycle of cytotoxic chemotherapy. **Alternative Biosimilar**			
☐ pegfilgrastim-apgf Syrg 6 mg			
6 mg, subcutaneous, Once, Starting at treatment start time Prior to use, remove the carton from the refrigerator and allow the prefilled syringe to reach room temperature for a minimum of 15-30 minutes. Do not administer to persons with latex allergies. Pegfilgrastim should be administered at least 24 hours after administration of cytotoxic chemotherapy. Pegfilgrastim should not be administered within 14 days prior to the next cycle of cytotoxic chemotherapy. **Non-preferred Biosimilar**			